Valsartan And Hydrochlorothiazide
Product Images NDC 71610-327

8 FDA label images from Aphena Pharma Solutions - Tennessee, Llc · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Valsartan And Hydrochlorothiazide (NDC 71610-327). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Bottle Label 320 mg/ 25 mg (71610 0327 60)

Bottle Label 320 mg/ 25 mg (71610 0327 60)
Label for Valsartan and Hydrochlorothiazide USP, 320mg/25mg, containing 90 tablets. The label includes storage instructions, manufacturer Macleods Pharmaceuticals Ltd., and distribution by Aphena Pharma Solutions - Tennessee, LLC in Cookeville, TN. The product is marked for RX only use.*
FDA Label Image

Aphena Pharma Solutions (TN)

Aphena Pharma Solutions (TN)
FDA Label Image

Figure-1 (Figure 1)

Figure-1 (Figure 1)
A line graph illustrating the percentage of patients with systolic blood pressure (SBP) below 140 mmHg across different baseline SBP levels (140-180 mmHg). The chart compares four groups: Valsartan HCT 320/25 mg, Valsartan 320 mg, Hydrochlorothiazide 25 mg, and Placebo, with distinct markers for each group.*
FDA Label Image

Figure-2 (Figure 2)

Figure-2 (Figure 2)
A line graph showing the percentage of patients achieving diastolic blood pressure below 90 mmHg (% DBP <90) plotted against baseline diastolic blood pressure (DBP) in mmHg. The graph compares four groups: Valsartan HCT 320/25 mg, Valsartan 320 mg, Hydrochlorothiazide 25 mg, and Placebo, indicated by different symbols and line patterns. The percentage decreases as baseline DBP increases across all groups.*
FDA Label Image

Figure-3 (Figure 3)

Figure-3 (Figure 3)
A line chart comparing the percentage of subjects achieving systolic blood pressure (SBP) below 130 mmHg by baseline SBP in mmHg. The graph includes four curves representing Valsartan HCT 320/25 mg, Valsartan 320 mg, Hydrochlorothiazide 25 mg, and Placebo treatments, showing their relative effectiveness across different baseline SBP values.*
FDA Label Image

Figure-4 (Figure 4)

Figure-4 (Figure 4)
A line graph showing the percentage of patients with diastolic blood pressure (DBP) less than 80 mmHg relative to baseline DBP (mmHg). The graph compares Valsartan and Hydrochlorothiazide 320/25 mg, Valsartan 320 mg, Hydrochlorothiazide 25 mg, and placebo, with distinct markers for each group as indicated in the legend.*
FDA Label Image

Valsartan (Valsartan)

Valsartan (Valsartan)
Chemical structure diagram of the active ingredient valsartan, showing its molecular framework with labeled atoms and bonds as part of the Valsartan and Hydrochlorothiazide product by Aphena Pharma Solutions - Tennessee, LLC.*
FDA Label Image

Hctz-str (Valsartn Hctz Str)

Hctz-str (Valsartn Hctz Str)
Chemical structure of Valsartan and Hydrochlorothiazide, showing the molecular arrangement with chlorine, sulfonamide, and other functional groups characteristic of these compounds.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.